Plaintiffs Renew Schering Off-Label Marketing Claims
A group of health and welfare funds, third-party payors and individual consumers have revamped their putative class action accusing Schering-Plough Corp. of illegally marketing its drugs Intron-A and Temodar for off-label...To view the full article, register now.
Already a subscriber? Click here to view full article